SR9009 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Joy Stevenson Heeley, lately Revenue Officer, Board of Inland Revenue. Thomas William Heler, Member, Staffordshire Parish Councils Association. For services to Local Government. Mabel Evelyn Jeanette Henderson. For services to the Guide Association in Shetland. Joan Elizabeth Hetherington. For public service. Major John Wilfred Barratt Hext, , Voluntary Observer, Meteorological Office, Cumbria. Sheila Jean Hibbert. For services to Young People in London. Herbert Vincent Higgins. For services to the Retired and Senior Volunteer Programme. Eileen Jeanne Hodder. For services to the community in Richmond upon Thames, Surrey. Eileen Hodgkinson. For political and public service Marjone Hodgson. For services to the community in York. Mavis Ruth Hogg. For services to Lawn Tennis. Olive Holden. For services to the Cancer Relief Macmillan Fund in Perthshire. David George Holland, Senior Road Safety Officer, Durham County Council. For services to Road Safety. John Kenneth Hollis. For charitable services in Kent. Thomas Holmes, lately Assistant Director, Environmental Services, Trafford Metropolitan Borough Council. For services to the Environment. Albert Joseph Thomas Honey. For services to Animal Welfare in Oxfordshire. James William Hopkins, lately Manager, District Office, East Midlands Electricity plc. For services to the Electricity Industry. Robert Hopper, Road Worker, Highways Division, Northumberland Contracting. For services to Highways Maintenance. Olive Mary Hopton. For services to the community in Irlam, Manchester. Beve Hornsby. For services to People with Dyslexia.
== Further reading == Barberis, Peter; McHugh, John; Tyldesley, Mike (1999). Encyclopedia of British and Irish Political Organizations. Pinter. p. 164. Boothroyd, David (2001). Politico's Guide to the History of British Political Parties. Politico's Publishing. p. 300. ISBN 1-902301-59-5. Perrin, David A. (2000). The Socialist Party of Great Britain: Politics, Economics and Britain's Oldest Socialist Party. Wrexham: Bridge Books. p. 123. ISBN 1-872424-80-5.
May 31: Decree regarding the admission of women to the role of Foreign Trade Advisor. June 14: The issuance of a passport no longer requires a husband's authorization for a married woman. September 30: Decree establishing a Higher Council for Child Protection. 1938
Sources: en.wikipedia.org
On 19 December, the National Guard stated that Syrian government forces in Rimat Hazim and Al-Mazra'a launched attacks towards Al-Majdal with drones and mortar fire, injuring two civilians, in addition to an infiltration by Syrian government forces on the northwest axis, resulting in four wounded. The National Guard accused Tareq al-Shoufi of "collaborating with Sharaa, and [he] went into hiding", while al-Hijri was "accused of kidnapping and his son of dealings with regional drug-smuggling networks, including Hezbollah." On 23 December, the National Guard stated that the Syrian government forces had “continued their attacks against al-Jabal and the surrounding areas”, using mortar fire, heavy machine guns, and drones. The city of Attil was attacked with mortar fire from Rimat Hazem and Tel Hadid, causing two deaths and eight injuries. There was also an attack on the civilian prison of Suwayda and transport directorate using heavy machine guns and mortar fire. On 24 December, clashes occurred between the National Guard and the Syrian government forces on the Ara-Khirbet Samar axis in the rural area of Suwayda and on the al-Majdal-al-Mazra'a axis, using 23mm heavy machine guns. That same day, the Royal Jordanian Air Force launched attacks on Suwayda that targeted “a series of factories and workshops that drug and arms traffickers use as bases to launch their illegal operations into Jordanian territory", It also attacked seven sites under the control of the National Guard, including a suspected weapons depot in Al Kafr, belonging to the Suwayda Military Council.
=== Endocrinopathies === The most commonly included disorders of the endocrine system are congenital hypothyroidism (CH) and congenital adrenal hyperplasia (CAH). Testing for both disorders can be done using blood samples collected on the standard newborn screening card. Screening for CH is done by measuring thyroxin (T4), thyrotropin (TSH) or a combination of both analytes. Elevated 17α-hydroxyprogesterone (17α-OHP) is the primary marker used when screening for CAH, most commonly done using enzyme-linked immunosorbant assays, with many programs using a second tier tandem mass spectrometry test to reduce the number of false positive results. Careful analysis of screening results for CAH may also identify cases of congenital adrenal hypoplasia, which presents with extremely low levels of 17α-OHP. When the immunoassay method is utilized as a screening method for quantifying 17α-OHP in dried blood spots, it exhibits a significant rate of false positive results. As per the clinical practice guideline issued by the Endocrine Society in 2018, employing LC-MS/MS to measure 17α-OHP and other adrenal steroid hormones (such as 21-deoxycortisol and androstenedione) is recommended as a supplementary screening approach to enhance the accuracy of positive predictions. CH was added to many newborn screening programs in the 1970s, often as the second condition included after PKU.
Treatment for overdose is supportive, and often involves aggressive cooling using methods such as ice baths and intravenous fluids. Grundlingh et al. recommend administering activated charcoal if the patient presents within an hour of ingestion and using intravenous vasopressors or inotropes to control blood pressure if necessary. Intravenous methylthioninium chloride can treat methaemoglobinaemia. Benzodiazepines can help control seizures and dantrolene has been used in an attempt to control hyperthemia. Cardiopulmonary resuscitation (CPR) has been used on people who died of DNP overdoses but has no known successful outcomes.
24 May – Andrew Shaw, children's television presenter, television director and producer (South Pacific Television, TVNZ), and media executive (TVNZ, South Pacific Pictures, NZ On Air) (born 1957). 29 May – David Trist, cricketer (Canterbury) and cricket coach (Eastern Province, national team) (born 1947). 30 May – John Pike, lawyer, King's Counsel (since 2013) (born 1944).
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.